FDA staffers weighs risks, rewards of new epilepsy drug

Staffers at the FDA have red-flagged their concern about cases of urinary retention tracked in some patients taking Valeant Pharmaceutical's experimental new epilepsy medicine Potiga (ezogabine), which comes before an advisory panel on Wednesday. But the staff review also noted that the drug appears to be effective and most cases of an inability to urinate were reversible.

Valeant is looking for an FDA approval to use the medicine as part of a combinational approach to partial onset seizures not adequately treated by existing remedies. And the agency spelled out its interest in the panel's views on the company's plans to monitor cases of urinary retention after it's approved for use. Valeant is developing the drug with GlaxoSmithKline and stands to gain up to half of the U.S. profits ginned by the therapy.

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee will gather the day after tomorrow to vote on the drug's safety and efficacy profile, offering guidance to the agency as it ponders a final decision on the drug.

- read the story from Reuters
- here's the Dow Jones report

Suggested Articles

The FDA has placed a phase 1/2 trial of Passage Bio’s GM1 gene therapy on clinical hold pending further assessment of the risk of its delivery device.

VBL got the green light after the committee looked at unblinded overall survival data for the second pre-planned interim analysis.

Eleusis researchers discovered that structural characteristics of the 2C-H class of psychedelics help to control asthma without behavioral effects.